Apalutamide

Therapeutic indications

Apalutamide is indicated for:

Non-metastatic castration-resistant prostate cancer (nmCRPC)

Population group: men, only adults (18 years old or older)

Apalutamide is indicated in adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 240 mg once daily

Metastatic hormone-sensitive prostate cancer (mHSPC)

Population group: men, only adults (18 years old or older)

Apalutamide is indicated in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 240 mg once daily

Contraindications

Apalutamide is contraindicated in the following cases:

Pregnancy

Pregnancy

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: ERLEADA Film-coated tablet
< Previous: Overview
Next: Precautions >